1 August 2017 - Business continuity plan aims to preserve Agency’s ability to protect public and animal health

The EMA has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s withdrawal from the European Union and the Agency’s relocation.

“Preparing for the move, managing the necessary changes, and addressing challenges such as possible losses in skilled and experienced staff, in a proactive and efficient way requires considerable internal resources,” said Noel Wathion, EMA’s Deputy Executive Director and head of EMA’s Brexit task force. "With the business continuity plan we aim to ensure that the assessment of medicines is not disrupted and that patients in Europe continue to have access to high quality, safe and effective medicines.”

Read EMA press release